Immuneering Corp. Class A IMRX 深 滬
已收盤 02-06 16:00:00 美东时间
4.93
+0.410
+9.07%
華盛通- 最 高5.0199
- 今 開4.62
- 成交量 157.67万股
- 最 低 4.60
- 昨 收 4.52
- 總市值 3.18亿
- 52周最高 10.08
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.10
- 委 比 -74.56%
- 總股本 6457.00万
- 歷史最高 33.99
- 量 比 1.38
- 振 幅 9.29%
- 歷史最低 1.00
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
01-07 23:03
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-12-25 00:06
Immuneering To Provide 12-Month Overall Survival From Its Current Phase 2a Clinical Study Of Atebimetinib + Modified Gemcitabine In Pancreatic Participants
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at
2025-12-23 21:03
Immuneering To Be Added To Nasdaq Biotechnology Index, Effective December 22
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology
2025-12-16 21:03
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immu...
2025-12-12 23:47
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Chardan Capital Maintains Buy on Immuneering, Maintains $20 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $20 price target.
2025-11-13 21:51
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
2025-11-03 20:20
